Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer.

Ross AE, Hurley PJ, Tran PT, Rowe SP, Benzon B, Neal TO, Chapman C, Harb R, Milman Y, Trock BJ, Drake CG, Antonarakis ES.

Prostate Cancer Prostatic Dis. 2019 Oct 14. doi: 10.1038/s41391-019-0176-8. [Epub ahead of print]

PMID:
31611635
2.

Clinical Significance of AR-V567es in Prostate Cancer-Response.

Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Giannakakou P.

Clin Cancer Res. 2019 Oct 1;25(19):6010-6011. doi: 10.1158/1078-0432.CCR-19-1820. No abstract available.

PMID:
31575715
3.

Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.

Taplin ME, Antonarakis ES, Ferrante KJ, Horgan K, Blumenstein B, Saad F, Luo J, de Bono JS.

Eur Urol. 2019 Sep 18. pii: S0302-2838(19)30684-0. doi: 10.1016/j.eururo.2019.08.034. [Epub ahead of print]

PMID:
31542304
4.

PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

Markowski MC, Chen Y, Feng Z, Cullen J, Trock BJ, Suzman D, Antonarakis ES, Paller CJ, Rosner I, Han M, Walsh PC, Partin AW, Eisenberger M.

Clin Genitourin Cancer. 2019 Aug 21. pii: S1558-7673(19)30251-4. doi: 10.1016/j.clgc.2019.08.002. [Epub ahead of print]

PMID:
31530439
5.

Targeting lineage plasticity in prostate cancer.

Antonarakis ES.

Lancet Oncol. 2019 Oct;20(10):1338-1340. doi: 10.1016/S1470-2045(19)30497-8. Epub 2019 Sep 9. No abstract available.

PMID:
31515155
6.

Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy.

VanderWeele DJ, Antonarakis ES, Carducci MA, Dreicer R, Fizazi K, Gillessen S, Higano CS, Morgans AK, Petrylak DP, Sweeney CJ, Hussain M.

J Clin Oncol. 2019 Sep 10:JCO1901595. doi: 10.1200/JCO.19.01595. [Epub ahead of print] No abstract available.

PMID:
31498754
7.

Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.

Deek MP, Yu C, Phillips R, Song DY, Deville C, Greco S, DeWeese TL, Antonarakis ES, Markowski M, Paller C, Denmeade S, Carducci M, Walsh PC, Pienta KJ, Eisenberger M, Tran PT.

Int J Radiat Oncol Biol Phys. 2019 Aug 13. pii: S0360-3016(19)33641-7. doi: 10.1016/j.ijrobp.2019.08.008. [Epub ahead of print]

8.

Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale.

Sedhom R, Antonarakis ES.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S341-S345. doi: 10.21037/tau.2019.05.02. No abstract available.

9.

Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.

Shenderov E, Isaacsson Velho P, Awan AH, Wang H, Mirkheshti N, Lotan TL, Carducci MA, Pardoll DM, Eisenberger MA, Antonarakis ES.

Prostate. 2019 Sep;79(13):1572-1579. doi: 10.1002/pros.23881. Epub 2019 Aug 7.

PMID:
31389628
10.

A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.

Paller CJ, Piana D, Eshleman JR, Riel S, Denmeade SR, Isaacsson Velho P, Rowe SP, Pomper MG, Antonarakis ES, Luo J, Eisenberger MA.

Prostate. 2019 Oct;79(14):1597-1603. doi: 10.1002/pros.23883. Epub 2019 Jul 30.

PMID:
31361358
11.

CDK12 inactivation across solid tumors: an actionable genetic subtype.

Marshall CH, Imada EL, Tang Z, Marchionni L, Antonarakis ES.

Oncoscience. 2019 May 10;6(5-6):312-316. doi: 10.18632/oncoscience.481. eCollection 2019 May.

12.

Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data.

Liu J, Near A, Chiarappa JA, Wada K, Tse J, Burudpakdee C, Behl A, Ranganath R, Antonarakis ES.

J Med Econ. 2019 Oct;22(10):1080-1087. doi: 10.1080/13696998.2019.1649267. Epub 2019 Aug 28.

PMID:
31352849
13.

Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.

Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS.

J Clin Invest. 2019 Jul 16;130:4245-4260. doi: 10.1172/JCI127613.

14.

Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.

Sokol ES, Pavlick D, Frampton GM, Ross JS, Miller VA, Ali SM, Lotan TL, Pardoll DM, Chung JH, Antonarakis ES.

Oncologist. 2019 Jul 10. pii: theoncologist.2019-0214. doi: 10.1634/theoncologist.2019-0214. [Epub ahead of print]

PMID:
31292271
15.

Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.

Armstrong AJ, Halabi S, Luo J, Nanus DM, Scher HI, Antonarakis ES, George DJ.

J Clin Oncol. 2019 Aug 20;37(24):2184-2186. doi: 10.1200/JCO.19.01230. Epub 2019 Jul 2. No abstract available.

PMID:
31265357
16.

Clinical implications of mismatch repair deficiency in prostate cancer.

Sedhom R, Antonarakis ES.

Future Oncol. 2019 Jul;15(20):2395-2411. doi: 10.2217/fon-2019-0068. Epub 2019 Jun 25.

PMID:
31237441
17.

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.

Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, Frampton GM, Bratslavsky G, Pal SK, Lee RJ, Necchi A, Gregg JP, Lara P Jr, Antonarakis ES, Miller VA, Ross JS, Ali SM, Agarwal N.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00283. Epub 2019 May 10.

18.

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).

Kapoor R, Deek MP, McIntyre R, Raman N, Kummerlowe M, Chen I, Gaver M, Wang H, Denmeade S, Lotan T, Paller C, Markowski M, Carducci M, Eisenberger M, Beer TM, Song DY, DeWeese TL, Hearn JW, Greco S, DeVille C, Desai NB, Heath EI, Liauw S, Spratt DE, Hung AY, Antonarakis ES, Tran PT.

BMC Cancer. 2019 Jun 13;19(1):572. doi: 10.1186/s12885-019-5805-z.

19.

Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.

Isaacsson Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FAS, Shaukat F, Carducci MA, Denmeade SR, Paller CJ, Markowski MC, Marshall CH, Eisenberger MA, Antonarakis ES.

Eur Urol. 2019 Jun 5. pii: S0302-2838(19)30439-7. doi: 10.1016/j.eururo.2019.05.032. [Epub ahead of print]

PMID:
31176623
20.

Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN; PCCTC Germline Genetics Working Group.

Clin Genitourin Cancer. 2019 Aug;17(4):275-282.e1. doi: 10.1016/j.clgc.2019.04.013. Epub 2019 Apr 18.

PMID:
31171481
21.

Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer.

Torquato S, Pallavajjala A, Goldstein A, Toro PV, Silberstein JL, Lee J, Nakazawa M, Waters I, Chu D, Shinn D, Groginski T, Hughes RM, Simons BW, Khan H, Feng Z, Carducci MA, Paller CJ, Denmeade SR, Kressel B, Eisenberger MA, Antonarakis ES, Trock BJ, Park BH, Hurley PJ.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00227. Epub 2019 Apr 3.

22.

Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations.

Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Hsieh AC, Nelson PS, Yu EY, Montgomery RB, True LD, Epstein JI, Lotan TL, Pritchard CC.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00327. Epub 2019 Apr 18.

23.

NCCN Guidelines Updates: Management of Prostate Cancer.

Mohler JL, Antonarakis ES.

J Natl Compr Canc Netw. 2019 May 1;17(5.5):583-586. doi: 10.6004/jnccn.2019.5011.

PMID:
31117038
24.

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.

PMID:
31085757
25.

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.

Morris MJ, Loriot Y, Sweeney CJ, Fizazi K, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Deandreis D, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS.

Eur J Cancer. 2019 Jun;114:107-116. doi: 10.1016/j.ejca.2019.04.007. Epub 2019 May 11.

26.

Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302.

Teply BA, Qiu F, Antonarakis ES, Carducci MA, Denmeade SR.

Prostate. 2019 Jun;79(8):929-933. doi: 10.1002/pros.23798.

PMID:
31059588
27.

Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?

Fay AP, Antonarakis ES.

Ann Transl Med. 2019 Mar;7(Suppl 1):S7. doi: 10.21037/atm.2019.01.37. No abstract available.

28.

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.

Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, Rasmussen J, Thornburg B, Berry WR, Wilder RS, Lu C, Chen Y, Silberstein JL, Kemeny G, Galletti G, Somarelli JA, Gupta S, Gregory SG, Scher HI, Dittamore R, Tagawa ST, Antonarakis ES, George DJ.

J Clin Oncol. 2019 May 1;37(13):1120-1129. doi: 10.1200/JCO.18.01731. Epub 2019 Mar 13.

PMID:
30865549
29.

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.

Marshall CH, Sokolova AO, McNatty AL, Cheng HH, Eisenberger MA, Bryce AH, Schweizer MT, Antonarakis ES.

Eur Urol. 2019 Oct;76(4):452-458. doi: 10.1016/j.eururo.2019.02.002. Epub 2019 Feb 21.

PMID:
30797618
30.

Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Carlo MI, Giri VN, Paller CJ, Abida W, Alumkal JJ, Beer TM, Beltran H, George DJ, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Ryan CJ, Schaeffer EM, Stadler WM, Taplin ME, Kauff ND, Vinson J, Antonarakis ES, Cheng HH.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00060. Epub 2018 Aug 16.

31.

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.

McHugh D, Eisenberger M, Heath EI, Bruce J, Danila DC, Rathkopf DE, Feldman J, Slovin SF, Anand B, Chu R, Lackey J, Reyno L, Antonarakis ES, Morris MJ.

Invest New Drugs. 2019 Oct;37(5):1052-1060. doi: 10.1007/s10637-019-00731-5. Epub 2019 Feb 6.

PMID:
30725389
32.

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer.

Antonarakis ES.

Oncologist. 2019 Apr;24(4):430-432. doi: 10.1634/theoncologist.2018-0819. Epub 2019 Jan 9. No abstract available.

33.

Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide.

Dib EG, Antonarakis ES, Wasco MJ, Powell SF.

Clin Genitourin Cancer. 2019 Apr;17(2):e365-e368. doi: 10.1016/j.clgc.2018.11.021. Epub 2018 Dec 6. No abstract available.

PMID:
30587403
34.

Targeting ELK1: a wELKome addition to the prostate cancer armamentarium.

Zarif JC, Antonarakis ES.

AME Med J. 2018 Oct;3. pii: 104. doi: 10.21037/amj.2018.10.08. Epub 2018 Oct 31. No abstract available.

35.

Selective inhibitors of nuclear export: potential therapeutics for AR variant-expressing prostate cancer.

Antonarakis ES.

Oncotarget. 2018 Nov 9;9(88):35797-35798. doi: 10.18632/oncotarget.26296. eCollection 2018 Nov 9. No abstract available.

36.

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.

Basch EM, Scholz M, de Bono JS, Vogelzang N, de Souza P, Marx G, Vaishampayan U, George S, Schwarz JK, Antonarakis ES, O'Sullivan JM, Kalebasty AR, Chi KN, Dreicer R, Hutson TE, Dueck AC, Bennett AV, Dayan E, Mangeshkar M, Holland J, Weitzman AL, Scher HI.

Eur Urol. 2019 Jun;75(6):929-937. doi: 10.1016/j.eururo.2018.11.033. Epub 2018 Dec 4.

37.

PARP inhibition - not all gene mutations are created equal.

Luo J, Antonarakis ES.

Nat Rev Urol. 2019 Jan;16(1):4-6. doi: 10.1038/s41585-018-0129-3. No abstract available.

PMID:
30498248
38.

AR-V7 and treatment selection in advanced prostate cancer: are we there yet?

Bastos DA, Antonarakis ES.

Precis Cancer Med. 2018 Sep;1. pii: 13. doi: 10.21037/pcm.2018.09.01. Epub 2018 Sep 18. No abstract available.

39.

Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.

Antonarakis ES, Shaukat F, Isaacsson Velho P, Kaur H, Shenderov E, Pardoll DM, Lotan TL.

Eur Urol. 2019 Mar;75(3):378-382. doi: 10.1016/j.eururo.2018.10.009. Epub 2018 Oct 15.

PMID:
30337059
40.

Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY.

Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, Stewart J, Zaher A, Szatrowski TP, Ballman KV, Kita K, Tasaki S, Bai Y, Portella L, Kirby BJ, Saad F, Eisenberger MA, Nanus DM, Giannakakou P.

Clin Cancer Res. 2019 Mar 15;25(6):1880-1888. doi: 10.1158/1078-0432.CCR-18-0320. Epub 2018 Oct 9.

41.

Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.

Isaacsson Velho P, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, Thorek DL, DeWeese TL, Song DY, Tran PT, Eisenberger MA, Antonarakis ES.

Eur Urol. 2019 Aug;76(2):170-176. doi: 10.1016/j.eururo.2018.09.040. Epub 2018 Oct 4.

PMID:
30293905
42.

Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer.

Antonarakis ES.

N Engl J Med. 2018 Sep 13;379(11):1087-1089. doi: 10.1056/NEJMcibr1808772. No abstract available.

PMID:
30207914
43.

Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.

Moyer CL, Phillips R, Deek MP, Radwan N, Ross AE, Antonarakis ES, Reyes D, Wright J, Terezakis SA, Song DY, DeVille C, Walsh PC, DeWeese TL, Carducci M, Schaeffer EM, Pienta KJ, Eisenberger M, Tran PT.

World J Urol. 2018 Sep 6. doi: 10.1007/s00345-018-2477-2. [Epub ahead of print]

PMID:
30191396
44.

Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage.

Marshall CH, Fu W, Wang H, Baras AS, Lotan TL, Antonarakis ES.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):59-65. doi: 10.1038/s41391-018-0086-1. Epub 2018 Aug 31.

45.

Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer.

Kang H, Antonarakis ES, Luo J, Zheng Q, Rooper L, De Marzo AM, Westra WH, Lotan TL.

Oral Oncol. 2018 Sep;84:134-136. doi: 10.1016/j.oraloncology.2018.06.026. Epub 2018 Jun 28. No abstract available.

PMID:
30122219
46.

Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies.

Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR, Pienta KJ, Antonarakis ES, Ross AE.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):539-548. doi: 10.1038/s41391-018-0061-x. Epub 2018 Jul 9.

47.

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.

Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES.

Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19.

48.

Reply to C. Ren et al.

Antonarakis ES.

J Clin Oncol. 2018 Aug 1;36(22):2356-2357. doi: 10.1200/JCO.2018.78.2680. Epub 2018 Jun 12. No abstract available.

PMID:
29894276
49.

Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?

Antonarakis ES.

Lancet Oncol. 2018 Jul;19(7):860-861. doi: 10.1016/S1470-2045(18)30409-1. Epub 2018 Jun 4. No abstract available.

PMID:
29880290
50.

Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.

Antonarakis ES, Small EJ, Petrylak DP, Quinn DI, Kibel AS, Chang NN, Dearstyne E, Harmon M, Campogan D, Haynes H, Vu T, Sheikh NA, Drake CG.

Clin Cancer Res. 2018 Oct 1;24(19):4662-4671. doi: 10.1158/1078-0432.CCR-18-0638. Epub 2018 Jun 1.

Supplemental Content

Loading ...
Support Center